Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.59 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851889 | 1.00 | MAP2K1 (0.62) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30584462 | 1.00 | MAP2K1 (0.62) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5989619 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5989612 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL23651905 | 0.89 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL26249791 | 0.88 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL24925752 | 0.86 | MAP2K1 (0.52) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL2025095 | 0.86 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL2025366 | 0.86 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29308283 | 0.86 | PIM1 (0.46) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006134469-A1 | METHODS OF PREPARING MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-12-21 | — | — | WO | claimed |
| US-7060856-B2 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY (US) | 2006-06-13 | — | — | US | claimed |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2023209611-A1 | METHODS OF TREATING CANCER WITH A B-RAF INHIBITOR, IN PARTICULAR LIFIRAFENIB | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212071-A1 | COMBINATION AND THE USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-02 | — | — | WO | disclosed |
| US-20230330047-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11571402-B2 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | SPRINGWORKS THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230032403-A1 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF | SpringWorks Therapeutics Inc. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2022177557-A1 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-1682495-A1 | POLYMORPHIC FORM OF N- (R)-2,3-DIHYDROXY-PROPOXY -3,4-D IFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-7060856-B2 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY (US) | 2006-06-13 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| WO-2005040098-A1 | POLYMORPHIC FORM OF N-[(R)-2,3-DIHYDROXY-PROPOXY]-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY | 2005-04-21 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | HLA-DRB1, UGT1A3, BBC3 | MAP2K1 4611/4885MAP2K2 4300/4885PIM1 4150/4885 |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885PIM1 1919/4885 |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | VHL, NRAS, KRAS | MAP2K1 3438/4885MAP2K2 3378/4885PIM1 3279/4885 |
| US-20230330047-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | QDPR, DHFR, NEFM | MAP2K1 4337/4885MAP2K2 3323/4885PIM1 1827/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885PIM1 2425/4885 |
| US-20230032403-A1 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF | NRAS, BRAF, KSR2 | MAP2K1 36/4885MAP2K2 19/4885PIM1 928/4885 |
| US-11571402-B2 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | FLNA, QDPR, DUT | MAP2K1 4460/4885MAP2K2 3808/4885PIM1 3602/4885 |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | QDPR, DHFR, NEFM | MAP2K1 4337/4885MAP2K2 3323/4885PIM1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.